Drugs.com - New Drug Approvals

U.S. FDA Approves Third Indication of Nubeqa (darolutamide) for Patients with Advanced Prostate cancer

Berlin, June 3, 2025 – Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved its oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT) for use in...

Jun 5, 2025 - 01:35
 0
U.S. FDA Approves Third Indication of Nubeqa (darolutamide) for Patients with Advanced Prostate cancer
Berlin, June 3, 2025 – Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved its oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT) for use in...
Read More

Tags:

Previous Article

Amneal Pharmaceutical LLC Issues a Nationwide Recall of Sulfamethoxazole / Trime...

Next Article

Home-Based Exercise, Coaching Improves Fitness in Neuromuscular Diseases

Related Posts

US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon Hadlima (adalimumab-bwwd) Injection

US Food and Drug Administration (FDA) Grants Interchang...

May 28, 2025  0

FDA Approves Merck’s Welireg (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)

FDA Approves Merck’s Welireg (belzutifan) for the Treat...

May 15, 2025  0

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) a...

May 12, 2025  0